Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PLX-PAD cells: Completed Phase I/II enrollment

Pluristem completed enrollment in a double-blind, placebo-controlled, German Phase I/II trial evaluating 2 doses of intramuscular

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE